XBIT News and Press, XBiotech Inc. From 01/21/21

After an analysis against mutant COVID-19 virus found in the U.K., XBiotech ([[XBIT]] +4.6%) says its COVID-19 candidate True Human™ antibody therapy may also be used for treating the new coronavirus strain.XBiotech’s candidate that specifically targets the so-called s...

AUSTIN, Texas, Jan. 21, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announces that its COVID-19 candidate True Human™ antibody therapy may also be used for treating the COVID-19 mutant virus that recently emerged in the UK and is now rapidly spreading across the US. The mut...

AUSTIN, Texas, Jan. 19, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today the first meeting of its Cerebrovascular Medical Advisory Board (CMAB). The CMAB is comprised of key opinion leaders who specialize in cerebrovascular diseases including ischemic stroke, which is t...

2020 was my second year writing for Seeking Alpha. Introspection and reflection are key tenets to invest by. To that end, here is a review of my 2020 Seeking Alpha write-ups and how the companies assessed have performed. For further details see: My 2020 Seeking Alpha Yea...

XBiotech Inc. is a clinical-stage biopharmaceutical company focused on developing safer/more effective therapeutics through human-based monoclonal antibodies. XBiotech's pipeline consists of 4 candidates with 3 in the pre-clinical phase. Starting 1-2Q 2021, XBiotech aims to re-enter t...

XBiotech (XBIT) announces new data for its candidate therapy for treating infections of influenza and COVID-19. The Company continues to analyze components of its FLUVID therapy.The True Human antibodies targeting the virus causing COVID-19 were found to effectively neutralize a test virus ab...

AUSTIN, Texas, Nov. 19, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today new data for its breakthrough candidate therapy for treating infections of influenza and COVID-19. The Company continues to analyze components of its so-called FLUVID™ therapy as it develops...

Pfizer and BioNTech's announcement that their COVID-19 vaccine candidate showed 90% efficacy based on a preliminary analysis of results from a pivotal study has stoked selling in therapy developers. If the higher-than-expected efficacy holds, herd immunity in the general population could pote...

XBiotech (XBIT) announces the launch of a new breakthrough candidate therapy called FLUVID for treating illness caused by combined infections with influenza and COVID-19.FLUVID therapy will combine XBiotech’s breakthrough influenza True Human antibodies together with its recently ...

AUSTIN, Texas, Sept. 21, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today it is developing a new breakthrough candidate therapy it calls FLUVID™ for treating illness caused by combined infections with influenza and COVID-19. With the global spread of the novel CO...